(Q24243136)

30 October 2023

Rafael Perera

3

R

Perera

2 references

ORCID Public Data File 2021

30 October 2023

Nicholas J Matheson

1

N J

Matheson

1 reference

30 October 2023

Anthony Harnden

series ordinal

2

author given names

A R

author last names

Harnden

1 reference

30 October 2023

Mkael Symmonds-Abrahams

series ordinal

5

author given names

M

author last names

Symmonds-Abrahams

1 reference

Cochrane Database of Systematic Reviews

30 October 2023

language of work or name

1 reference

24 January 2007

0 references

published in

0 references

cites work

Risk for respiratory events in a cohort of patients receiving inhaled zanamivir: a retrospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Use of Oseltamivir to control influenza complications after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Safety and pharmacology of oseltamivir in clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

The effect of zanamivir treatment on influenza complications: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Neuraminidase inhibitors in the management of influenza--experience of an outpatient practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Investigation of the Reconsultation Rate and Pharmacoeconomic Evaluation of Period of Influenza Treatment by Oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Role of viruses in the pathogenesis of acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Influenza and the rates of hospitalization for respiratory disease among infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Amantadine and rimantadine for preventing and treating influenza A in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Community study of role of viral infections in exacerbations of asthma in 9-11 year old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Estimating household and community transmission parameters for influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Avian flu: isolation of drug-resistant H5N1 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Neuraminidase inhibitors for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Viruses as precipitants of asthma symptoms. I. Epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Evaluation of diagnostic tests for influenza in a pediatric practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Guidelines on neuraminidase inhibitors in children are not supported by evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Risk of acute otitis media in relation to the viral etiology of infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Position statement: global neuraminidase inhibitor susceptibility network

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

7 January 2021

Influenza virus resistance to neuraminidase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

7 January 2021

A Longitudinal Study of Respiratory Viruses and Bacteria in the Etiology of Acute Otitis Media with Effusion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

7 January 2021

Prevalence of Various Respiratory Viruses in the Middle Ear during Acute Otitis Media

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

7 January 2021

Respiratory distress associated with zanamivir

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

7 January 2021

An evidence based approach to reducing antibiotic use in children with acute otitis media: controlled before and after study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

1 reference

7 January 2021

Effect of Influenza Treatment with Oseltamivir on Health Outcome and Costs in Otherwise Healthy Children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

7 January 2021

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB2

7 January 2021

10.1002/14651858.CD002744.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_bojtwuhvangn3gelnkfgbgk6hu

0 references